Biotech Values

[oc631]

management was already guiding investors to stop thinking of VRTX as an HCV company.

Just to clarify. VRTX wants investors (as of April 2013) to believe they are still a player in HCV. Not a has been. There may be some substance to this given the scarcity value within the Uridine nuke class (VX-135).